Convergent Therapeutics is a pharmaceutical company with a mission to target and treat cancer through radiotherapies. Aiming to create therapies for prostate cancer, the company’s CONV01-α treatment is being explored in addition to other common cancer treatments including chemotherapy, hormone therapy, and immunotherapy. Convergent Therapeutics was founded in 2021 by Neil Bander and Philip Kantoff and is headquartered in Cambridge, MA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
09/24/2024 | Series A-4 | $40MM | $xx.xx | $269.38MM | Novo Holdings | |
Price per Share
$xx.xx
Shares Outstanding
19,898,516
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Novo Holdings
|
||||||
05/03/2023 | Series A-3 | $5.18MM | $xx.xx | $186.01MM | Orbimed, Ra Capital Management, The Invus Group | |
Price per Share
$xx.xx
Shares Outstanding
4,783,404
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Orbimed, Ra Capital Management, The Invus Group
|
||||||
05/03/2023 | Series A-2 | $3.14MM | $xx.xx | $186.01MM | Orbimed, Ra Capital Management, The Invus Group | |
Price per Share
$xx.xx
Shares Outstanding
2,542,409
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Orbimed, Ra Capital Management, The Invus Group
|
||||||
05/03/2023 | Series A-1 | $81.68MM | $xx.xx | $186.01MM | Orbimed, Ra Capital Management, The Invus Group | |
Price per Share
$xx.xx
Shares Outstanding
52,821,240
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Orbimed, Ra Capital Management, The Invus Group
|